•   
  •   

Health Imugene gains 10pc on cancer vaccine progress; 3 other biotechs getting patents

07:25  07 april  2021
07:25  07 april  2021 Source:   stockhead.com.au

ScoPo’s powerplays: Antisense ‘looks like it wants to run harder’

  ScoPo’s powerplays: Antisense ‘looks like it wants to run harder’ Power's pick this week is Antisense Therapeutics (ASX:ANP), a biopharmaceutical company that is researching a potential treatment for Duchenne's muscular Read More The post ScoPo’s powerplays: Antisense ‘looks like it wants to run harder’ appeared first on Stockhead.

a person in a blue shirt: Imugene cancer vaccine © Stockhead Australia Imugene cancer vaccine

Imugene (ASX:IMU) shares have hit an all-time high after the Sydney biotech company announced its cancer vaccine was continuing to show early promise in a small clinical trial.

A cohort review committee has allowed the Phase 1 trial to move into its highest dosing cohort after finding no adverse effects in any of the seven lung cancer patients who had received smaller doses of PD1-Vaxx — while in several, their tumours had stabilised or even apparently disappeared.

Two patients had shown a “complete response,” meaning their tumours were non-measurable, while four had shown stabilisation of disease. Just one patient’s tumours had gotten worse.

Kylie Jenner donates $500,000 to Monroe Carell Jr. Children's Hospital

  Kylie Jenner donates $500,000 to Monroe Carell Jr. Children's Hospital Kylie Jenner was recently the target of backlash after she was accused of not donating 'enough' to a GoFundMe supporting her injured former makeup artist. But the KUWTK star, 23, may have just silenced her critics as it was revealed Wednesday she donated $500,000 to Monroe Carell Jr. Children's Hospital at Vanderbilt located in Nashville, Tennessee.Jenner's hefty donation, as well as monetary assistance given by Roger Daltrey and Pete Townshend's Teen Cancer America, went towards the construction of a patient space, called the 'Hey, I'm Here For You Teen Lounge.

“Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development,” said Imugene managing director and chief executive Leslie Chong.

“I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx phase 1 trial.”

Clinical results suggest that the therapy is working as designed, with patients developing antibodies to the PD1 biomarker, a checkpoint protein that cancer cells use to hide from the body’s immune system.


Video: TGA meeting to determine causal link with blood clots (ABC NEWS)

For the third and final stage of the study, at least three cancer patients will receive 100 micrograms of PD1-Vaxx, double the dose of the previous cohort.

Ovarian Cancer Is Often Found Too Late, so What Are the Symptoms To Look Out For?

  Ovarian Cancer Is Often Found Too Late, so What Are the Symptoms To Look Out For? Ovarian cancer is known as the most lethal gynaecological cancer there is. One woman in Australia dies from this disease every eight hours, and according to data from the American Cancer Society, 60% of women are not diagnosed with ovarian cancer until the disease has spread to other tissue. The data is bleak, but the powerful news to take here is that if detected early enough, the Ovarian Cancer Research Foundation (OCRF) states that over 90% of patients can be cured. So, how do we improve the rates of early detection? Currently, there is no early detection test for ovarian cancer.

Volpara, Immutep and Medlab

Elsewhere, Volpara Health Technologies (ASX:VHT) said it had received a US patent and Immutep (ASX:IMM) announced it had received a European one, while Medlab Clinical (ASX:MDC) said it would be getting a European patent soon.

Volpara said its latest patent – its 96th – protects key features of its clinical system software, which helps clinicians monitor workflow efficiency and work quality while taking mammograms.

Immutep said its European patent covers a humanised form of an Immutep antibody that’s licensed to Novartis, in conjunction with a Novartis anti-PD1 antibody molecule that’s somewhat similar to Imugene’s. (Many companies are looking to build on the blockbuster success of PD1 inhibitors like Bristol Myers Squibb‘s Opdivo and Merck‘s Keytruda)

Lastly, Medlab said the European Patent Office had sent it a notice it intended to grant the company a patent for its NanoCelle sub-micron delivery platform. Medlab said that “NanoCelle creates nano-sized water-soluble particles … overcoming issues with solubility and degradation.”

At 11.53am, Imugene shares were up 11.5 per cent to 14.5c; Medlab was up 8.3 per cent to 26c; Volpara was up 3 per cent to $1.37; and Immutep was up 1.2 per cent to 43c.

The post Imugene gains 10pc on cancer vaccine progress; 3 other biotechs getting patents appeared first on Stockhead.

9 medical reasons you need to wee all the time .
Frequent trips to the bathroom could be normal – or it might be something serious. Here's how to know. The post 9 medical reasons you need to wee all the time appeared first on Reader's Digest Australia.

usr: 2
This is interesting!